Atara Biotherapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Atara Biotherapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Atara Biotherapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Atara Biotherapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Atara Biotherapeutics Inc (Atara) is a biotechnology company focused on developing T-cell immunotherapies. The company's main activities involve leveraging its allogeneic Epstein-Barr virus (EBV) T-cell platform to create therapies for cancer and autoimmune diseases. One of its major products is Tab-Cel, also known as Ebvallo, which is used for treating EBV-associated post-transplant lymphoproliferative disease. Its product pipeline includes tab-cel (Ebvallo) for the treatment of EBV+ post-transplant lymphoproliferative disease (EBV+ PTLD) and ATA3219, an allogeneic CAR T therapy targeting CD19. Atara's products are primarily used by healthcare providers to treat patients with high unmet medical needs in the oncology and autoimmune sectors. Atara targets markets in the European Economic Area, the United Kingdom, Switzerland, and the United States. Atara is headquartered in Thousand Oaks, California, the US.
Headquarters
United States of America
Address
1280 Rancho Conejo Blvd, Thousand Oaks, California, 91320
Website
www.atarabio.com
Telephone
1 805 6234211
No of Employees
14
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ATRA (NASD)
Revenue (2024)
$120.8M
-6.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
138.3%
(2024 vs 2023)
Market Cap*
$73.2M
Net Profit Margin (2024)
XYZ
140.9%
(2024 vs 2023)
* As of and is in US$
Atara Biotherapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Product Pipeline: | Ebvallo |
| Tabelecleucel (tab-cel): Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) | |
| ATA3219: Non-Hodgkin’s Lymphoma (NHL), Lupus Nephritis (LN) | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Divestiture | In July, the company sold the Investigational New Drug Application for tabelecleucel to Pierre Fabre Pharmaceuticals, Inc. |
| 2024 | Regulatory Approval | In February, the company received US Food and Drug Administration (FDA) approval for an Investigational New Drug (IND) application for ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell monotherapy for the treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]). |
| 2023 | Divestiture | In November, the company sold its marketing rights to Ebvallo (tabelecleucel) in North America, Asia Pacific, and Latin America to Pierre Fabre Laboratories. |
Competitor Comparison
| Key Parameters | Atara Biotherapeutics Inc | Novartis AG | Bristol-Myers Squibb Co | Allogene Therapeutics Inc | F. Hoffmann-La Roche Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | Switzerland |
| City | Thousand Oaks | Basel | Princeton | San Francisco | Basel |
| State/Province | California | Basel-Stadt | New Jersey | California | - |
| No. of Employees | 14 | 75,267 | 32,500 | 150 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Greg Ciongoli | Chairman | Executive Board | 2025 | 50 |
| Cokey Nguyen | Chief Executive Officer; Director; President | Executive Board | 2024 | 53 |
| Yanina Grant-Huerta | Chief Accounting Officer | Senior Management | - | - |
| Jim Sesic | Senior Vice President - Regulatory Affairs | Senior Management | - | - |
| John Chao | Head - Legal | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer